US House of Representatives votes in favor of 21st Century Cures Act

13 July 2015

The US House of Representatives has voted 344 to 77 in favor of the 21st Century Cures Act, which would speed up the approval of drugs and medical devices and boost funding for research.

The implementation of the bill would require the US Food and Drug Administration to streamline the approval process, consider more flexible forms of clinical trials and incorporate patient experience into decision-making. The bill would mean increased funding for the National Institutes of Health and the FDA over the next five years, respectively almost $8.75 billion and $550 million.

FDA would consider physicians' experience

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK